It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NMRA’s FA Score shows that 1 FA rating(s) are green whileZ’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NMRA’s TA Score shows that 5 TA indicator(s) are bullish while Z’s TA Score has 7 bullish TA indicator(s).
NMRA (@Biotechnology) experienced а -17.21% price change this week, while Z (@Internet Software/Services) price change was +0.11% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.75%. For the same industry, the average monthly price growth was +12.94%, and the average quarterly price growth was +4.02%.
The average weekly price growth across all stocks in the @Internet Software/Services industry was -1.25%. For the same industry, the average monthly price growth was +0.23%, and the average quarterly price growth was +9.96%.
NMRA is expected to report earnings on Aug 12, 2025.
Z is expected to report earnings on Jul 31, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Internet Software/Services (-1.25% weekly)Companies in this industry typically license software on a subscription basis and it is centrally hosted. Such products usually go by the names web-based software, on-demand software and hosted software. Cloud computing has emerged as a major force in this space, making it possible to save files to a remote database (without requiring them to be saved on local storage device); as long as a device has access to the web, it can access the data and the software programs to run it. This has in many cases facilitated cost efficiency, speed and security of data for businesses and consumers. Alphabet Inc., Facebook, Inc. and Yahoo! Inc. are some well-known names in the internet software/services industry.
NMRA | Z | NMRA / Z | |
Capitalization | 137M | 11.2B | 1% |
EBITDA | -262.83M | 104M | -253% |
Gain YTD | -92.033 | -4.970 | 1,852% |
P/E Ratio | N/A | 129.87 | - |
Revenue | 0 | 1.95B | - |
Total Cash | 308M | 2.81B | 11% |
Total Debt | 1.85M | 1.83B | 0% |
Z | ||
---|---|---|
OUTLOOK RATING 1..100 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 86 | |
SMR RATING 1..100 | 90 | |
PRICE GROWTH RATING 1..100 | 50 | |
P/E GROWTH RATING 1..100 | 99 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NMRA | Z | |
---|---|---|
RSI ODDS (%) | 2 days ago90% | N/A |
Stochastic ODDS (%) | 2 days ago90% | 2 days ago77% |
Momentum ODDS (%) | 2 days ago90% | 2 days ago76% |
MACD ODDS (%) | N/A | 2 days ago82% |
TrendWeek ODDS (%) | 2 days ago87% | 2 days ago76% |
TrendMonth ODDS (%) | 2 days ago87% | 2 days ago76% |
Advances ODDS (%) | 6 days ago86% | 11 days ago79% |
Declines ODDS (%) | 2 days ago87% | 24 days ago79% |
BollingerBands ODDS (%) | 2 days ago90% | 2 days ago76% |
Aroon ODDS (%) | 2 days ago77% | 2 days ago77% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
JEPRX | 13.91 | -0.10 | -0.71% |
JPMorgan Equity Premium Income R6 | |||
NSFGX | 11.60 | -0.10 | -0.85% |
Natixis Target Retirement 2035 N | |||
CSVFX | 21.46 | -0.33 | -1.51% |
Columbia International Div Inc Inst | |||
MSCGX | 10.75 | -0.17 | -1.56% |
Mercer US Small/Mid Cap Equity Y3 | |||
LCMGX | 18.76 | -0.36 | -1.88% |
Lord Abbett Micro Cap Growth C |
A.I.dvisor indicates that over the last year, NMRA has been loosely correlated with NGNE. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if NMRA jumps, then NGNE could also see price increases.
Ticker / NAME | Correlation To NMRA | 1D Price Change % | ||
---|---|---|---|---|
NMRA | 100% | -5.94% | ||
NGNE - NMRA | 38% Loosely correlated | -3.14% | ||
ABOS - NMRA | 37% Loosely correlated | -6.14% | ||
AURA - NMRA | 36% Loosely correlated | -3.75% | ||
SNDX - NMRA | 35% Loosely correlated | -3.94% | ||
INZY - NMRA | 34% Loosely correlated | +0.25% | ||
More |
A.I.dvisor indicates that over the last year, Z has been closely correlated with ZG. These tickers have moved in lockstep 99% of the time. This A.I.-generated data suggests there is a high statistical probability that if Z jumps, then ZG could also see price increases.